Cadrenal Therapeutics, Inc. Annual Report: A Plain-English Guide

I am writing this guide to help you understand how Cadrenal Therapeutics performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

Cadrenal is a clinical-stage drug company. They do not sell any products yet, so they have no sales revenue. Their main focus is developing CAD-1005 (tecarfarin). This is a blood thinner designed for patients with heart pumps (LVADs). Unlike standard blood thinners, CAD-1005 avoids common drug interactions and genetic issues. They are also researching another drug, frunexian, for wider use.

2. Major changes this year

In December 2025, the company shifted its strategy by acquiring the tecarfarin platform. They are now fully focused on getting CAD-1005 approved by the FDA. In March 2026, they met with the FDA to discuss their plans. The FDA confirmed they could potentially use a single Phase 3 trial to support their application. This path saves the company significant time and money.

3. Financial health: The "Burn"

Cadrenal reported $0 in sales this year. They lost about $12.4 million, mostly spent on research and administrative costs.

• The Reality: The company had about $4.2 million in cash at the end of the year. They spend roughly $800,000 to $1 million each month. This means they have enough cash to last only 4 to 6 months.
• What this means for you: The upcoming Phase 3 trial will cost between $15 million and $25 million. To pay for it, the company must raise more money. They will likely issue more shares, which reduces your ownership percentage in the company.

4. Key risks: What could go wrong?

• The Funding Gap: Auditors warned that the company may not have enough cash to operate for the next 12 months. If they cannot raise money or find a partner, they may have to shut down.
• Regulatory Hurdles: Even with "Fast Track" status, FDA approval is not guaranteed. The FDA might demand more safety data, which would increase costs and cause delays.
• Intellectual Property: The company licenses its main drug from a university. If they miss payments or break the contract, they could lose the rights to the drug. Also, the original patents for the drug have expired. They now rely on newer, narrower patents that offer less protection against generic competitors.
• Stock Volatility: As a small biotech company, the stock price can swing wildly based on rumors or news. They also rely on outside companies to run their trials. If those partners fail or delay work, the company’s timeline will suffer.

5. Future outlook

The company is at a "make or break" point. They must raise at least $20 million to start their Phase 3 trial. Their long-term goal is to prove the drug works for heart pump patients and then expand to other uses.

Final thought for your decision: Treat this as a high-stakes investment. The company’s value depends almost entirely on the success of this upcoming trial, and there are no sales to fall back on if the results are disappointing. Before investing, consider whether you are comfortable with the high probability of share dilution and the significant risk that the company may need to raise capital just to keep the lights on.